Niharika Mettu is an Oncology physician affiliated with Duke University. OpenAlex indexes 163 publications with 855 citations (h-index 14); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
20 Duke Medicine Cir
Durham, NC 277102000
Telephone
919-684-8111Registry record last updated 22 Jul 2014.
Clinical trials
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Sponsor: Academic and Community Cancer Research United
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Becton, Dickinson and CompanyProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
44.9%Phenothiazine15.4%Prochlorperazine Maleate100%Part D≥26 patientsSNRI9.2%Duloxetine Hcl100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
35.6%Serotonin-3 Receptor Antagonist19.2%Ondansetron Hcl100%Part D≥30 patientsProton pump inhibitor7.5%Pantoprazole Sodium100%Part D<11 patients+ 2 more classes in this area
Sensory organs
12.3%Corticosteroid12.3%Dexamethasone100%Part D≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and biomarker assessment of ST316, a novel peptide antagonist of ß-catenin, in patients with advanced solid tumors.
Journal of Clinical Oncology
2025 - Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
JNCI Journal of the National Cancer Institute
2024 - Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”